DekaBank Deutsche Girozentrale increased its position in G1 Therapeutics Inc (NASDAQ:GTHX) by 22.3% during the 1st quarter, HoldingsChannel.com reports. The fund owned 11,500 shares of the company’s stock after buying an additional 2,100 shares during the period. DekaBank Deutsche Girozentrale’s holdings in G1 Therapeutics were worth $691,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other institutional investors and hedge funds have also recently made changes to their positions in GTHX. Legal & General Group Plc grew its position in G1 Therapeutics by 20.0% in the 4th quarter. Legal & General Group Plc now owns 4,060 shares of the company’s stock worth $78,000 after purchasing an additional 676 shares during the last quarter. American International Group Inc. grew its position in G1 Therapeutics by 8.5% in the 4th quarter. American International Group Inc. now owns 15,004 shares of the company’s stock worth $287,000 after purchasing an additional 1,177 shares during the last quarter. Rhumbline Advisers grew its position in G1 Therapeutics by 5.6% in the 1st quarter. Rhumbline Advisers now owns 29,815 shares of the company’s stock worth $495,000 after purchasing an additional 1,569 shares during the last quarter. Two Sigma Advisers LP grew its position in G1 Therapeutics by 7.0% in the 4th quarter. Two Sigma Advisers LP now owns 28,900 shares of the company’s stock worth $553,000 after purchasing an additional 1,900 shares during the last quarter. Finally, Alps Advisors Inc. grew its position in G1 Therapeutics by 4.5% in the 1st quarter. Alps Advisors Inc. now owns 89,816 shares of the company’s stock worth $1,491,000 after purchasing an additional 3,885 shares during the last quarter. Hedge funds and other institutional investors own 73.35% of the company’s stock.
GTHX has been the topic of several recent research reports. Cowen reiterated a “buy” rating on shares of G1 Therapeutics in a research report on Wednesday, March 6th. Zacks Investment Research upgraded shares of G1 Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, March 20th. BidaskClub lowered shares of G1 Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, March 1st. Finally, Wedbush reaffirmed an “outperform” rating and issued a $67.00 target price on shares of G1 Therapeutics in a research note on Friday, March 1st. Three investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. G1 Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $60.43.
Shares of NASDAQ GTHX opened at $18.55 on Wednesday. The company has a market cap of $699.57 million, a P/E ratio of -7.25 and a beta of 2.22. G1 Therapeutics Inc has a 52-week low of $13.87 and a 52-week high of $69.57.
G1 Therapeutics (NASDAQ:GTHX) last issued its quarterly earnings data on Thursday, May 9th. The company reported ($0.64) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.69) by $0.05. Equities analysts forecast that G1 Therapeutics Inc will post -2.91 EPS for the current year.
ILLEGAL ACTIVITY WARNING: “G1 Therapeutics Inc (NASDAQ:GTHX) Position Lifted by DekaBank Deutsche Girozentrale” was first posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this piece of content can be read at https://www.thelincolnianonline.com/2019/06/12/g1-therapeutics-inc-nasdaqgthx-position-lifted-by-dekabank-deutsche-girozentrale.html.
G1 Therapeutics Company Profile
G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase Ib/II clinical trials for patients with extensive-stage small cell lung cancer, as well as Phase II clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; lerociclib, an oral CDK4/6 inhibitor that is in Phase Ib/IIa clinical trials for the treatment of breast cancer and in Phase Ib/II clinical trial for non-small cell lung cancer; and G1T48, an oral selective estrogen receptor degrader, which is in Phase I clinical trial.
Read More: Why does a company issue an IPO?
Want to see what other hedge funds are holding GTHX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for G1 Therapeutics Inc (NASDAQ:GTHX).
Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.